We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IMXI:NASDAQInternational Money Express, Inc. Analysis

Data as of 2026-04-10 - not real-time

$15.81

Latest Price

3/10Risk

Risk Level: Low

Executive Summary

International Money Express (IMXI) is trading at $15.81, just above its 20‑day SMA of $15.80 and comfortably within a narrow 30‑day volatility band of ~2.9%. The stock shows a bullish trend direction but the MACD histogram has turned negative, signaling short‑term weakness, while the RSI sits at a neutral 56. Recent insider buying by CEO Robert Lisy adds a positive sentiment cue, yet the latest earnings report missed EPS expectations and revenue fell 10.5% year‑over‑year. Technical support sits at $15.73 and resistance at $15.90, leaving limited upside of roughly 1‑2%.
Fundamentally, IMXI trades at a forward PE of 8.3 versus an industry average of 34, suggesting relative cheapness, but the DCF fair value of $4.80 marks the stock as severely overvalued at current levels. The company carries a high debt‑to‑equity ratio of 134% and a modest free cash flow generation, while operating in a heavily regulated, globally dispersed remittance market that adds regulatory and geographic risk. With no dividend and a “hold” analyst consensus, the balance of technical modesty, earnings miss, and elevated debt points to a cautious stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Insider purchase by CEO signals confidence
  • Technical support near current price
  • Q1 earnings miss and revenue decline

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • DCF indicates significant overvaluation
  • High debt‑to‑equity ratio
  • Stable but low volume liquidity

Long Term

> 3 years
Cautious
Model confidence: 4/10

Key Factors

  • Elevated regulatory and geographic exposure
  • Weak revenue growth trajectory
  • Heavy leverage limiting financial flexibility

Key Metrics & Analysis

Financial Health

Revenue Growth-10.50%
Profit Margin5.38%
P/E Ratio14.6
ROE22.08%
ROA9.10%
Debt/Equity134.44
P/B Ratio2.9
Op. Cash Flow$36.9M
Free Cash Flow$14.2M
Industry P/E34.1

Technical Analysis

TrendBullish
RSI56.6
Support$15.73
Resistance$15.90
MA 20$15.80
MA 50$15.71
MA 200$14.29
MACDBearish
VolumeStable
Fear & Greed Index87.27

Valuation

Fair Value$4.80
Target Price$16.00
Upside/Downside1.23%
GradeOvervalued
TypeValue

Risk Assessment

Beta0.37
Volatility2.86%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.